Japan· JP-6241013F2225
レボフロキサシン水和物
A levofloxacin product containing レボフロキサシン水和物, registered in Japan by 高田製薬, on the national reimbursement list. The same ATC class is registered in 17 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Levofloxacin is registered in 17 of 19 countries.
Countries holding a registration under ATC J01MA12 (levofloxacin), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 10 of them publish a price we can compare per daily dose
Levofloxacin · ATC J01MA12
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of levofloxacin costs, country by country.
Normalised to the WHO defined daily dose (0.24 g), the median price runs from $0.68 in Italy to $3.14 in Switzerland — a ×4.6 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Levofloxacin · price per daily dose (0.24 g)
USD · FX 28 Sept 2026
- CH Switzerland$3.14
- IT Italy$0.68
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- レボフロキサシン水和物
- Manufacturer
- 高田製薬
- Country
- Japan (JP)
- ATC code
- J01MA12
- ATC class
- Levofloxacin
- Defined daily dose
- 0.24 g, Inhal
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
593 interactions on record for levofloxacin.
Graded by severity as the source publishes them — 125 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Levofloxacin · interactions on record
593 records
- 125 severe
- 341 moderate
- 52 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- PrednisoloneA07EA01severe
75 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J01MA12
Levofloxacin, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bb1036bb-c163-4768-976c-d1e6276690c1 GET /v1/drugs/bb1036bb-c163-4768-976c-d1e6276690c1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "２５０ｍｇ１錠（レボフロキサシンとして）",
"marks": "局",
"source": "mhlw",
"remarks": null,
"yj_code": "6241013F2225",
"category": "内用薬",
"price_yen": 24.7,
"generic_name": "レボフロキサシン水和物",
"product_name_jp": null,
"therapeutic_class": "6241",
"transitional_expiry": null
}See everything about levofloxacin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.